Patent Application for SLIT2 Related Compositions and Methods
Summary
The USPTO has published a new patent application (US20260085111A1) filed by EVEREST MEDICINES (SINGAPORE) PTE. LTD. The application relates to antibodies that bind to SLIT2 and related substitution mutants, including their manufacture and use.
What changed
This document is a publication of a patent application filed by EVEREST MEDICINES (SINGAPORE) PTE. LTD. The application, identified as US20260085111A1, details compositions and methods involving antibodies that bind to SLIT2 and related substitution mutants. The filing date was September 18, 2023, and the publication date is March 26, 2026.
As this is a patent application, it does not impose immediate regulatory obligations or penalties on other entities. However, it signifies potential future intellectual property rights related to SLIT2 therapeutics. Companies operating in the pharmaceutical or biotechnology sectors, particularly those involved in drug development or antibody research, should be aware of this filing as it may impact their own research and development strategies or patent landscape.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SLIT2 RELATED COMPOSITIONS AND METHODS
Application US20260085111A1 Kind: A1 Mar 26, 2026
Assignee
EVEREST MEDICINES (SINGAPORE) PTE. LTD.
Inventors
Jie ZHAO, Shan HE, Wei Jennifer YANG, He LI
Abstract
The antibodies bind to SLIT2 and related substitution mutants, including their manufacture and use.
CPC Classifications
C07K 16/18 A61P 13/12 A61K 2039/505 C07K 2317/24 C07K 2317/52 C07K 2317/565 C07K 2317/92
Filing Date
2023-09-18
Application No.
19112728
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.